Article

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence Scores

2021-05-13

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold> A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 893ea4e2-10d3-5ab1-b6d8-e5effc9bc3ee
DOI: 10.21203/rs.3.rs-496843/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresDOI 10.21203/rs.3.rs-496843/v1Read

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.Semantic proximity Read

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read

Evaluation of 95-Gene Classifier of Formalin-Fixed Paraffin-Embedded Tissues in ER-Positive, HER2-Negative, and Node-Negative Breast CancerSemantic proximity Read

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

Impact of Different Modules of 21-Gene Assay in Early Breast Cancer PatientsSemantic proximity Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read